Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Organogenesis Holdings Inc. (ORGO)
Sector: Healthcare; Industry: Drug Manufacturers—Specialty & Generic

Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-11-24 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 2,839 $4.99 $14,171 No
2020-11-19 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 4,404,162 $3.29 $14,500,672 No
2020-11-17 KATZ MICHAEL W 10%-Owner Buy 20,829 $3.25 $67,694 No
2020-11-17 MACKIE WAYNE D Director Buy 42,726 $3.25 $138,860 No
2020-11-17 Leibowitz Arthur S Director Buy 6,943 $3.25 $22,565 No
2020-11-17 NUSSDORF GLENN H 10%-Owner, Director Buy 833,153 $3.25 $2,707,747 No
2020-11-17 Ades Alan A. 10%-Owner, Director Buy 833,153 $3.25 $2,707,747 No
2020-03-16 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 542,349 $3.98 $2,160,957 No
2019-11-26 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 6,000,000 $5.00 $30,000,000 No
2019-09-13 KATZ MICHAEL W 10%-Owner Buy 3,603 $6.00 $21,618 No
2019-09-13 MACKIE WAYNE D Director Buy 4,990 $6.13 $30,570 No
2019-09-12 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 860,900 $5.99 $5,155,772 No
2019-09-11 MACKIE WAYNE D Director Buy 13,010 $5.30 $69,017 No
2019-09-10 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 537,000 $5.18 $2,782,529 No
2019-09-06 NUSSDORF GLENN H 10%-Owner, Director Buy 10,000 $5.03 $50,274 No
2019-09-06 Ades Alan A. 10%-Owner, Director Buy 10,000 $5.03 $50,274 No
2019-09-03 Leibowitz Arthur S Director Buy 5,000 $4.20 $21,000 No
2019-09-04 MACKIE WAYNE D Director Buy 82,000 $4.47 $366,211 No
2019-09-04 KATZ MICHAEL W 10%-Owner Buy 10,000 $4.50 $44,975 No
2019-09-05 NUSSDORF GLENN H 10%-Owner, Director Buy 105,100 $4.50 $473,209 No
2019-09-05 Ades Alan A. 10%-Owner, Director Buy 105,100 $4.50 $473,209 No
2019-09-05 Avista Capital Managing Member IV, LLC 10%-Owner, Director Buy 577,600 $4.84 $2,797,551 No

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.